Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
Open Access
Abstract
NAPOLI-1 (NCT01494506) was a phase III study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. This post hoc analysis of NAPOLI-1 aimed to develop a predictive nomogram for overall survival (OS) at 6 and 12 months. Analyses were derived from all patients in NAPOLI-1 randomized to receive nal-IRI+5-FU/LV, nal-IRI monotherapy, or 5-FU/LV combination therapy. OS was associated with baseline factors using univariate and multivariable Cox analyses. A predictive nomogram was derived and validated using a concordance index and calibration plots. The univariate analyses identified 21 independent factors that contributed to OS, with eight factors significantly associated with OS. The Karnofsky Performance Score contributed the largest number of points (100), followed by presence of liver metastasis (98) and randomization to nal-IRI+5-FU/LV (96). The other baseline factors showing effects were albumin (g/dL), neutrophil/lymphocyte ratio, carbohydrate antigen 19-9 (U/mL), disease stage at diagnosis, and body mass index (kg/m2). The nomogram was used to predict the 6- and 12-month survival probability. The mean absolute errors between the observed and predicted probabilities for OS at 3, 6, and 9 months were 0.07, 0.08, and 0.07, respectively. This nomogram, based on NAPOLI-1, provides additional insight to aid decision-making for patients with mPDAC after previous gemcitabine-based therapy.Keywords
Funding Information
- Ipsen Biopharmaceuticals (N/A)
- Merrimack Pharmaceuticals, Inc (N/A)
This publication has 27 references indexed in Scilit:
- Clinical Characteristics of Long-Term Survivors of Inoperable Pancreatic CancerPancreas, 2014
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- European cancer mortality predictions for the year 2014Annals of Oncology, 2014
- Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapyBritish Journal of Cancer, 2014
- Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biologyAdvanced Drug Delivery Reviews, 2014
- A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinomaAnnals of Oncology, 2013
- Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancerBritish Journal of Cancer, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Nomograms for staging, prognosis, and predicting treatment outcomesCancer, 2009
- How To Build and Interpret a Nomogram for Cancer PrognosisJournal of Clinical Oncology, 2008